Skip to main content

Catalyst Calendar

Scope

Mon, Aug 24, 2026

1 updates
ARWR
7:30 AM

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

- Detailed results from the Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia will be presented as a HOT LINE Late-Breaking Science Session on August 30, 2026 - - Arrowhead will host a webcast to review ESC data and Q&A on August 31, 2026 - PASADENA,

Presentation / Abstract • Phase 3ESC Late-Breaking Science Session Sun, Aug 30, 2026, 5:30 PM CESTarrowheadpharma.com

Mon, Aug 17, 2026

1 updates

Tue, Aug 4, 2026

2 updates
ARWR
4:01 PM

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

- Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Aug. 4, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026.

Presentation / Abstract • Phase 3ESC Congress Hot Line Late Breaker presentation Sun, Aug 30, 2026arrowheadpharma.com
ARWR
4:00 PM

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

- Voucher to be used to accelerate review of a planned sNDA for plozasiran in severe hypertriglyceridemia PASADENA, Calif. --(BUSINESS WIRE)--Aug. 4, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has signed an agreement with an undisclosed third party to acquire a

arrowheadpharma.com

Mon, Aug 3, 2026

1 updates

Mon, Jul 27, 2026

1 updates
ARWR
7:30 AM

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

- Study completion anticipated in mid-2027 PASADENA, Calif. --(BUSINESS WIRE)--Jul. 27, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the company’s investigational RNA interference

Enrollment • Phase 3Enrollment milestone Mon, Jul 27, 2026arrowheadpharma.com

Wed, Jul 22, 2026

1 updates
ARWR
7:30 AM

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

Deep, durable, and consistent median triglyceride reductions of 79% and 81% from baseline in SHASTA -3 and SHASTA -4, respectively Statistically significant reduction in acute pancreatitis events versus placebo across the entire sHTG study population, with an unprecedented 100% event reduction in

Trial Results • Phase 3ESC Late Breaker presentation Sun, Aug 30, 2026, 5:30 PM CESTarrowheadpharma.com

Tue, Jul 21, 2026

1 updates
ARWR
7:30 AM

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

PASADENA, Calif. --(BUSINESS WIRE)--Jul. 21, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 third quarter ended June 30, 2026.

arrowheadpharma.com

Mon, Jun 22, 2026

1 updates
ARWR
12:33 PM

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing

arrowheadpharma.com

Thu, Jun 18, 2026

1 updates

Tue, Jun 2, 2026

1 updates
ARWR
7:30 AM

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

PASADENA, Calif. --(BUSINESS WIRE)--Jun. 2, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2026 Jefferies Global Healthcare Conference – June 2-4, 2026 Type: Fireside Chat Presentation Date/Time: June 3,

arrowheadpharma.com